- Home
- REX vs CERT Comparison
REX vs CERT Comparison
Compare REX & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | CERT |
|---|---|---|
| Founded | 1980 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Retail: Computer Software & Peripheral Equipment |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | REX | CERT |
|---|---|---|
| Price | $41.46 | $7.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 134.0K | ★ 2.4M |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $650,487,000.00 | $418,838,000.00 |
| Revenue This Year | $19.45 | $4.18 |
| Revenue Next Year | N/A | $5.39 |
| P/E Ratio | $73.64 | ★ N/A |
| Revenue Growth | 1.24 | ★ 8.75 |
| 52 Week Low | $30.02 | $4.45 |
| 52 Week High | $53.36 | $13.88 |
Technical Indicators
Market Signals| Indicator | REX | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 54.73 |
| Support Level | $32.04 | $7.86 |
| Resistance Level | $41.79 | $8.39 |
| Average True Range (ATR) | 1.64 | 0.32 |
| MACD | -0.10 | -0.06 |
| Stochastic Oscillator | 26.76 | 34.31 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company that engages in investments in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include Ethanol, dried distillers grains, modified distillers grains, Distillers corn oil, Modified distillers grains, and Other.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.